Search
Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase
go.drugbank.com/bio_entities/BE0001402TargetVACVInvolved in the modification of both mRNA ends and in intermediate and late gene positive transcription elongation. … At the mRNAs 5' end, methylates the ribose 2' OH group of the first transcribed nucleotide, thereby producing a 2'-O-methylpurine cap.
Polypeptides: Cap-specific mRNA (nucleoside-2'-O-)-methyltransferaseEnfuvirtide
go.drugbank.com/drugs/DB00109ApprovedInvestigationalThe first agent in the novel class of antiretroviral drugs called HIV fusion inhibitors, enfuvirtide works by inhibiting HIV-1 fusion with CD4 cells. … Enfuvirtide is a 36 amino acid biomimetic peptide that is structurally similar to the HIV proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake
Categories: Amino Acids, Peptides, and ProteinsFluoxymesterone
go.drugbank.com/drugs/DB01185ApprovedIllicitAn anabolic steroid that has been used in the treatment of male hypogonadism, delayed puberty in males, and in the treatment of breast neoplasms in women.
Categories: Genito Urinary System and Sex Hormones, Sex Hormones and Modulators of the Genital SystemSynonyms: 9-Fluoro-11β,17β-dihydroxy-17-methylandrost-4-en-3-oneBirch bark extract
go.drugbank.com/drugs/DB16536ApprovedInvestigational[L42390] Filsuvez was subsequently approved for the same indication by the US FDA in December 2023. … skin, mucous membranes, and internal epithelial linings characterized by extreme skin fragility and blister development.
Diroximel fumarate
go.drugbank.com/drugs/DB14783ApprovedInvestigationalDiroximel fumarate was formulated by Alkermes in collaboration with Biogen, and was approved by the FDA in October 2019[L9626] and by the EMA in November 2021.[L39225] … Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life.
Categories: Antineoplastic and Immunomodulating AgentstRNA-dihydrouridine(20) synthase [NAD(P)+]-like
go.drugbank.com/bio_entities/BE0020091EnzymeHumansSpecifically modifies U20 in cytoplasmic tRNAs (PubMed:38680565). Activity depends on the presence of guanosine at position 19 in the tRNA substrate (PubMed:38680565). … Catalyzes the NADPH-dependent synthesis of dihydrouridine, a modified base found in the D-loop of most tRNAs (PubMed:15994936, PubMed:26429968, PubMed:30149704, PubMed:34798057, PubMed:38680565).
Synonyms: Up-regulated in lung cancer protein 8Partial Seizures With Secondary Generalization
go.drugbank.com/conditions/DBCOND0061516Drugs: CarbamazepineSynonyms: Focal to bilateral tonic-clonic seizure, FBTCS - focal to bilateral tonic-clonic seizureGimeracil
go.drugbank.com/drugs/DB09257ApprovedInvestigationalApproved by the European Medicines Agency (EMA) in March 2011, Gimeracil is available in combination with [DB03209] and [DB09256] within the commercially available product "Teysuno". … It functions by reversibly and selectively blocking the enzyme dihydropyrimidine dehydrogenase (DPD), which is involved in the degradation of 5-FU [A31408].
Synonyms: Ts-1 (TN)Lusutrombopag
go.drugbank.com/drugs/DB13125ApprovedInvestigationalLusutrombopag is currently in phase III development in various European countries including Austria, Belgium, Germany, and the UK [A36730]. … Lusutrombopag is an orally bioavailable thrombopoietin receptor (TPOR) agonist developed by Shionogi & Company (Osaka, Japan).
Categories: Blood and Blood Forming OrgansLumacaftor
go.drugbank.com/drugs/DB09280ApprovedInvestigational[A20343] Improvements in lung function (ppFEV1) were found to be statistically significant, but minimal, with only a 2.6-3.0% change from baseline with more than 70% of patients failing to achieve an absolute … Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, a transmembrane ion
Categories: ivacaftor and lumacaftor